A Study of the Involvement of Melanin-Concentrating Hormone Receptor 1 (MCHR1) in Murine Models of Depression
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. Biological Psychiatry
(Impact Factor: 10.26).
02/2007; 61(2):174-80. DOI: 10.1016/j.biopsych.2006.03.076
Most antidepressant medications target central monoamine systems and are often characterized by limited efficacies and unwanted side effects. Thus, significant efforts are ongoing to identify novel targets for the treatment of depression. Growing evidence suggests that neuropeptides play a role in the pathophysiology of depression. The melanin-concentrating hormone (MCH) is one such neuropeptide, implicated in the modulation of many physiological responses.
We utilized an array of techniques including chronic mild stress (CMS) as a depression paradigm, neurobehavior, gene expression analysis, and knockout genetics to investigate the role of MCH receptor subtype 1 (MCHR1) in murine models of depression.
We report here that following a 5-week exposure to repeated chronic mild stress (an ethologically relevant animal model of depression), C57Bl/6J mice have increased hippocampal gene expression of MCH receptor subtype 1 (MCHR1), the cognate melanin concentrating hormone receptor in mice. This increased gene expression is reversed by chronic fluoxetine hydrochloride (Prozac) treatment. Additionally, while female and male mice carrying a null mutation of the MCHR1 gene show comparable anxiolytic-like behavior on the open field, only female knockout mice exhibit antidepressant-like behavior, when tested on the forced swim and tail suspension tests.
Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women.
Available from: Frank Martin Schmidt
- "A body of preclinical findings points towards an impact of MCH-activity on depression-like behavior and suggests possible treatment options via alteration of MCH (Chung et al., 2011). Most investigations on animals report a depressiogenic effect of MCH whereas antagonizing MCH-action by receptor-modulation could lead to reduced depressive behavior (Georgescu et al., 2005; Lagos et al., 2011; Borowsky et al., 2002; Roy et al., 2007). Our results of missing group differences do not indicate a hyper-or hyposecretion of MCH within untreated depressed subjects. "
[Show abstract] [Hide abstract]
ABSTRACT: In preclinical studies, the hypothalamic polypeptide melanin-concentrating hormone (MCH) has been shown to be involved in depression-like behavior and modulations of MCH and MCH-receptors were proposed as potential new antidepressant drug targets.
For the first time, MCH serum levels were explored in 30 patients with major depressive disorder (MDD) prior to (T1) and after 2 (T2) and 4 weeks (T3) of antidepressant treatment and in 30 age- and sex-matched healthy controls by applying a fluorescence immunoassay.
Levels of MCH did not differ significantly between un-medicated patients (444.11±174.63pg/mL SD) and controls (450.68±210.03pg/mL SD). In MDD patients, MCH levels significantly decreased from T1 to T3 (F=4.663; p=0.013). Post-hoc analyses showed that these changes were limited to patients treated with mirtazapine but not escitalopram and female but not male patients. MCH-levels showed high correlations from T1 to T3 (r≥0.964, p<0.001) and were found to correlate significantly with parameters of sleep within the controls.
Small sample size. No follow-up measures were performed within the control group.
Our findings suggest peripheral MCH-levels not to be altered in depression but possibly reflecting depression-related state properties that can be modulated by sleep, medication and sex.
Copyright © 2015 Elsevier B.V. All rights reserved.
Journal of Affective Disorders 04/2015; 180:207-213. DOI:10.1016/j.jad.2015.03.039 · 3.38 Impact Factor
- "It was discovered that MCHR1 antagonists also exert anxiolytic and antidepressant effects (Borowsky et al., 2002), which led to the investigation of other physiological functions of the MCH system. In recent years, MCH has been implicated in the regulation of metabolism, reward, anxiety and depression-like behaviors, sleep, learning and memory, and seizure threshold, among other functions (Chaki et al., 2005; Chung et al., 2009; Garcia-Fuster et al., 2012; Lagos et al., 2009; Lee et al., 2011; Parks et al., 2010; Qu et al., 1996; Roy et al., 2007; Shimada et al., 1998; Verret et al., 2003). MCH is regarded as an inhibitory peptide, because MCHR1 couples to G i /G o and typically inhibits the activity of postsynaptic target neurons (Gao and van den Pol, 2001, 2002). "
[Show abstract] [Hide abstract]
ABSTRACT: Melanin-concentrating Hormone (MCH) is a 19 amino acid cyclic neuropeptide that acts in rodents via the MCH receptor 1 (MCHR1) to regulate a wide variety of physiological functions. MCH is produced by a distinct population of neurons located in the lateral hypothalamus (LH) and zona incerta (ZI) but MCHR1 mRNA is widely expressed throughout the brain. The physiological responses and behaviors regulated by the MCH system have been investigated, but less is known about how MCH neurons are regulated. The effects of most classical neurotransmitters on MCH neurons have been studied, but those of neuropeptides are poorly understood. In order to gain insight into how neuropeptides regulate the MCH system, we investigated which neuropeptide receptors are expressed by MCH neurons using double in situ hybridization. In all, twenty receptors, selected based upon either a suspected interaction with the MCH system or demonstrated high expression levels in the LH and ZI, were tested to determine whether they are expressed by MCH neurons. Overall, eleven neuropeptide receptors were found to exhibit significant colocalization with MCH neurons: Nociceptin / Orphanin FQ Opioid receptor (NOP), MCHR1, both Orexin receptors (ORX), Somatostatin receptor 1 and 2 (SSTR1, SSTR2), the Kisspeptin receotor (KissR1), Neurotensin receptor 1 (NTSR1), Neuropeptide S receptor (NPSR), Cholecystokinin receptor A (CCKAR) and the κ-opioid receptor (KOR). Of these receptors, six have never before been linked to the MCH system. Surprisingly, several receptors thought to regulate MCH neurons displayed minimal colocalization with MCH, suggesting that they may not directly regulate the MCH system. J. Comp. Neurol., 2014. © 2014 Wiley Periodicals, Inc.
The Journal of Comparative Neurology 12/2014; 522(17). DOI:10.1002/cne.23642 · 3.23 Impact Factor
Available from: Kenkichi Takase
- "There have been contradictory reports about the anxiety-related behavior of MCH signaling-deficient mice , , , , . Our meta-analysis did not produce clear conclusions regarding the effects of MCH signaling deficiency on anxiety; weak anxiolytic effects were found for in the elevated plus maze and open field tests, but weak anxiogenic effects were found in the emergence test. "
[Show abstract] [Hide abstract]
ABSTRACT: The demand for meta-analyses in basic biomedical research has been increasing because the phenotyping of genetically modified mice does not always produce consistent results. Melanin-concentrating hormone (MCH) has been reported to be involved in a variety of behaviors that include feeding, body-weight regulation, anxiety, sleep, and reward behavior. However, the reported behavioral and metabolic characteristics of MCH signaling-deficient mice, such as MCH-deficient mice and MCH receptor 1 (MCHR1)-deficient mice, are not consistent with each other. In the present study, we performed a meta-analysis of the published data related to MCH-deficient and MCHR1-deficient mice to obtain robust conclusions about the role of MCH signaling. Overall, the meta-analysis revealed that the deletion of MCH signaling enhanced wakefulness, locomotor activity, aggression, and male sexual behavior and that MCH signaling deficiency suppressed non-REM sleep, anxiety, responses to novelty, startle responses, and conditioned place preferences. In contrast to the acute orexigenic effect of MCH, MCH signaling deficiency significantly increased food intake. Overall, the meta-analysis also revealed that the deletion of MCH signaling suppressed the body weight, fat mass, and plasma leptin, while MCH signaling deficiency increased the body temperature, oxygen consumption, heart rate, and mean arterial pressure. The lean phenotype of the MCH signaling-deficient mice was also confirmed in separate meta-analyses that were specific to sex and background strain (i.e., C57BL/6 and 129Sv). MCH signaling deficiency caused a weak anxiolytic effect as assessed with the elevated plus maze and the open field test but also caused a weak anxiogenic effect as assessed with the emergence test. MCH signaling-deficient mice also exhibited increased plasma corticosterone under non-stressed conditions, which suggests enhanced activity of the hypothalamic-pituitary-adrenal axis. To the best of our knowledge, the present work is the first study to systematically compare the effects of MCH signaling on behavioral and metabolic phenotypes.
PLoS ONE 06/2014; 9(6):e99961. DOI:10.1371/journal.pone.0099961 · 3.23 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.